Wealth Enhancement Advisory Services LLC acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 53,052 shares of the biopharmaceutical company’s stock, valued at approximately $3,601,000.

A number of other large investors have also added to or reduced their stakes in GILD. Creative Financial Designs Inc. ADV raised its position in shares of Gilead Sciences by 55.9% during the first quarter. Creative Financial Designs Inc. ADV now owns 460 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 165 shares during the last quarter. Trustcore Financial Services LLC purchased a new position in Gilead Sciences in the 1st quarter valued at approximately $34,000. Weaver Consulting Group purchased a new position in Gilead Sciences in the 1st quarter valued at approximately $34,000. Legacy Advisors LLC purchased a new position in Gilead Sciences in the 2nd quarter valued at approximately $37,000. Finally, Founders Capital Management boosted its position in Gilead Sciences by 50.0% in the 1st quarter. Founders Capital Management now owns 600 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 200 shares during the period. 78.87% of the stock is currently owned by institutional investors and hedge funds.

Several equities analysts have commented on GILD shares. Citigroup set a $78.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Wednesday, July 31st. Goldman Sachs Group lowered shares of Gilead Sciences from a “neutral” rating to a “sell” rating and dropped their price objective for the company from $70.00 to $60.00 in a research note on Tuesday, May 28th. Morgan Stanley set a $82.00 target price on shares of Gilead Sciences and gave the company a “hold” rating in a report on Monday, July 15th. BidaskClub downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating in a report on Wednesday, June 5th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a report on Monday, July 15th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have assigned a buy rating and two have assigned a strong buy rating to the stock. Gilead Sciences has a consensus rating of “Buy” and an average target price of $82.29.

In other Gilead Sciences news, EVP Brett A. Pletcher sold 5,816 shares of the stock in a transaction on Tuesday, June 18th. The shares were sold at an average price of $68.75, for a total transaction of $399,850.00. Following the transaction, the executive vice president now directly owns 27,198 shares in the company, valued at approximately $1,869,862.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Brett A. Pletcher sold 7,200 shares of the stock in a transaction on Tuesday, July 23rd. The stock was sold at an average price of $65.07, for a total transaction of $468,504.00. Following the sale, the executive vice president now directly owns 34,398 shares in the company, valued at $2,238,277.86. The disclosure for this sale can be found here. Corporate insiders own 0.20% of the company’s stock.

GILD traded down $0.04 during trading on Thursday, hitting $63.08. 2,967,581 shares of the company’s stock were exchanged, compared to its average volume of 6,220,770. The company has a current ratio of 3.76, a quick ratio of 3.67 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a 1 year low of $60.32 and a 1 year high of $79.61. The stock’s 50 day moving average is $66.33. The stock has a market capitalization of $81.03 billion, a price-to-earnings ratio of 10.26, a P/E/G ratio of 3.04 and a beta of 1.16.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.68 by $0.14. The company had revenue of $5.69 billion during the quarter, compared to the consensus estimate of $5.54 billion. Gilead Sciences had a net margin of 26.64% and a return on equity of 37.12%. Gilead Sciences’s revenue for the quarter was down 2.8% on a year-over-year basis. During the same period in the previous year, the firm earned $1.91 earnings per share. Sell-side analysts forecast that Gilead Sciences, Inc. will post 6.65 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 27th. Shareholders of record on Friday, September 13th will be paid a dividend of $0.63 per share. The ex-dividend date is Thursday, September 12th. This represents a $2.52 dividend on an annualized basis and a yield of 3.99%. Gilead Sciences’s dividend payout ratio (DPR) is 40.98%.

Gilead Sciences Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Featured Story: What are economic reports?

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.